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Abstract
Introduction: The human epidermal growth factor receptor 2 (HER2) is an established biomarker for management
of patients with breast cancer. While conventional testing of HER2 protein expression is based on semi-quantitative
visual scoring of the immunohistochemistry (IHC) result, efforts to reduce inter-observer variation and to produce
continuous estimates of the IHC data are potentiated by digital image analysis technologies.
Methods: HER2 IHC was performed on the tissue microarrays (TMAs) of 195 patients with an early ductal
carcinoma of the breast. Digital images of the IHC slides were obtained by Aperio ScanScope GL Slide Scanner.
Membrane connectivity algorithm (HER2-CONNECT™, Visiopharm) was used for digital image analysis (DA). A
pathologist evaluated the images on the screen twice (visual evaluations: VE1 and VE2). HER2 fluorescence in situ
hybridization (FISH) was performed on the corresponding sections of the TMAs. The agreement between the IHC
HER2 scores, obtained by VE1, VE2, and DA was tested for individual TMA spots and patient’s maximum TMA spot
values (VE1max, VE2max, DAmax). The latter were compared with the FISH data. Correlation of the continuous
variable of the membrane connectivity estimate with the FISH data was tested.
Results: The pathologist intra-observer agreement (VE1 and VE2) on HER2 IHC score was almost perfect: kappa
0.91 (by spot) and 0.88 (by patient). The agreement between visual evaluation and digital image analysis was
almost perfect at the spot level (kappa 0.86 and 0.87, with VE1 and VE2 respectively) and at the patient level
(kappa 0.80 and 0.86, with VE1max and VE2max, respectively). The DA was more accurate than VE in detection of
FISH-positive patients by recruiting 3 or 2 additional FISH-positive patients to the IHC score 2+ category from the
IHC 0/1+ category by VE1max or VE2max, respectively. The DA continuous variable of the membrane connectivity
correlated with the FISH data (HER2 and CEP17 copy numbers, and HER2/CEP17 ratio).
Conclusion: HER2 IHC digital image analysis based on membrane connectivity estimate was in almost perfect
agreement with the visual evaluation of the pathologist and more accurate in detection of HER2 FISH-positive
patients. Most immediate benefit of integrating the DA algorithm into the routine pathology HER2 testing may be
obtained by alerting/reassuring pathologists of potentially misinterpreted IHC 0/1+ versus 2+ cases.
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Recent progress of virtual microscopy and digital image
analysis technologies opens new perspectives for the devel-
opment of more reliable tools of tissue-based biomarker
measurement [1-4]. This would enable high-throughput
research, quality assurance, and decision-support measures
to control for observer variability. Not surprisingly, the
dawn of digital pathology is marked by the efforts to opti-
mise image analysis algorithms for HER2 expression in
breast cancer tissue [4-7]. They all aim at ensuring accu-
rate and reproducible measurement of HER2 expression,
which correlates with pathologist’s evaluation, amplifica-
tion of the gene and clinical outcomes. In the absence of a
true “gold standard”, the objectivity of image analysis tools
can also be tested by inter-algorithm variation studies [8].
Some studies have compared outputs of various tools for
HER2 IHC analysis [9,10]. Computer-aided digital micro-
scopy has been shown to reduce observer variability in
HER2 IHC evaluation [11].
We designed our study to test the performance of HER2
IHC scoring based on a novel membrane connectivity esti-
mate in tissue microarrays (TMAs) of breast cancer tissue.
The digital analysis (DA) results were compared with the
data of visual evaluation (VE) of HER2 by IHC and HER2
FISH test results on the same TMAs.
Materials and methods
Tumour Specimens
Tumour samples were obtained from prospectively col-
lected series of 195 patients with an early invasive ductal
carcinoma of the breast treated at the Oncology Institute
of Vilnius University and investigated at the National
Center of Pathology during the period of 2007 to 2009.
The median age of the patients was 57 years (range 27-87
years). The patients were diagnosed with stage T1-2
tumours, without distant metastases (M0), however, 48%
of the patients showed lymph node involvement (N1 or
N2). Informed consent was obtained and documented in
writing before study entry. The study was approved by
the Lithuanian Bioethics Committee.
Tissue Microarrays
The TMAs were constructed from 10% buffered formalin-
fixed paraffin-embedded tissue blocks, selected by the
pathologist (DD). The corresponding hematoxylin and
eosin-stained slides were scanned by Aperio ScanScope
GL Slide Scanner (Aperio Technologies, Vista, CA, USA)
under 20 × magnification. The pathologist randomly
selected and marked representative areas of the tumour
on the whole section images. The images were then con-
verted into Mirax MViewMRXS format and used to guide
the production of the TMAs on the tissue arraying instru-
ment (3DHISTECH, TMA Master, Budapest, Hungary).
One millimetre-diameter cores were punched from the
selected areas, thus producing 11 TMAs blocks containing
737 spots from 195 patients. Paraffin sections of the
TMAs were cut for IHC (3 μm-thick) and FISH testing (4
μm-thick).
Immunohistochemistry
The sections were immunostained on Ventana Bench-
Mark XT staining system (Ventana Medical Systems, Tuc-
son, Arizona, USA). Sections were deparaffinized in
xylene, dehydrated through three alcohol changes and
transferred to Ventana Wash solution. Epitope retrieval
was performed on the slides using Cell Conditioning solu-
tion (pH 8.5) at 100°C for 36 min. The sections were then
incubated with Ventana PATHWAY anti-HER2/neu (4B5)
rabbit monoclonal antibody at 37°C for 16 min using Ven-
tana Ultraview DAB detection kit. Finally, the sections
were developed in DAB at 37°C for 8 min, counterstained
with Mayer’s hematoxylin and mounted. Whole tissue sec-
tions of HER2-positive breast tumour tissue were used as
positive tissue controls, while negative controls were per-
formed by omitting the application of primary antibody.
Digital images were captured using the Aperio ScanScope
GL Slide Scanner (Aperio Technologies, Vista, CA, USA)
under 20 × magnification.
Visual evaluation of HER2 IHC images
Visual evaluation of HER2 IHC score was performed by
the pathologist (DD) twice (VE1, VE2) with an interval of
2 months, based on the review of the images of individual
spots on the computer monitor (Acer AL2616W). The
IHC results were scored according to the United States
Food and Drug Administration (FDA) criteria approved
for the 4B5 HER2 rabbit monoclonal antibody. Each spot
was graded individually with 0, 1+, 2+ or 3+ HER2 score.
For further analysis the score 0 and 1+ was merged into
negative (0/1+) HER2 category. Based on the common
adequacy criteria (tissue integrity, presence and amount
of tumour tissue, staining artefacts), the pathologist
encoded individual spots as inadequate. Similarly, spots
containing ductal carcinoma in situ (DCIS), with or with-
out invasive carcinoma, were excluded from further
analysis.
Digital analysis of HER2 IHC images
Digital analysis of the HER2 IHC TMAs was performed
on the same images as the visual evaluation. By using
the Arrayimager software module from Visiopharm
(Hoersholm, Denmark), individual digital images of each
spot were automatically extracted from the whole slide
images of the 11 TMAs. For each spot, a region-of-
interest (ROI) was fully automatically defined by the tis-
sue detecting algorithm of the Visiomorph software
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against the potential effect on digital analysis of possibly
artificial staining of the edge of the tissue spot, the ROI
was designed to have a distance to the nearest edge of
100 pixels (approximately 25 μm). Automatic area con-
trol ensured exclusion of severely destroyed or missing
spots from the study, sin c eat i s s u es p o tw a so n l y
included, if its ROI area exceeded 37,000 μm
2,c o r r e -
sponding to approximately 5% of the ROI of an intact
spot with a diameter of 1 mm. The spots containing
inadequate tumour sample or DCIS were excluded from
the DA by means of visual evaluation.
As recently described in detail [12], the DA was per-
formed by the HER2-CONNECT™ software module (Vis-
iopharm, Hoersholm, Denmark). Briefly, the algorithm of
this software includes: 1) pre-processing for detection of
pixels contributing to the characteristic brown linear
structures in digital images of tissue sections immunos-
tained for the presence of HER2 by the DAB substrate; 2)
bimodal segmentation for distinguishing pixels represent-
ing stained membrane from all other pixels of the image;
3) post-processing for skeletonizing the membrane, mer-
ging membranes which were not perfectly connected, and
eliminating small membrane fragments. The values of
variable parameters used in the pre-processing, segmenta-
tion and post-processing were all established in a preced-
ing study at NordiQC (Aalborg Hospital, Denmark) using
different staining methods, another whole slide scanner,
and manual outlining of ROI [12]. The parameters were
not specifically optimized for the current study. The size
of each membrane fragment is defined as the area of pixels
its skeleton is composed of, and the connectivity is calcu-
lated from the size distribution of all membrane fragments
within the ROI. The connectivity can vary continuously
from 0, corresponding to a ROI without a single mem-
brane fragment with an area larger than a pre-defined low
cut-off, to 1, corresponding to a ROI for which all mem-
brane fragments have areas larger than a pre-defined high
cut-off. The continuous connectivity estimate was then
converted into HER2 score: 0/1+ if connectivity ≤ 0.12, 2+
if 0.12 < connectivity ≤ 0.56, 3+ if 0.56 < connectivity ≤ 1,
Figure 1.
Fluorescence in situ hybridization
HER2 gene amplification was determined by a dual
color FISH using the PathVysion HER2 DNA probe kit
and Paraffin pretreatment kit (Abbott-Vysis, Inc., Down-
ers Grove, IL, USA). Briefly, 4 μm sections were placed
on positively charged slides and dried overnight at 56°C.
The sections were deparaffinized in xylene, dehydrated
in alcohol, air dried, then pretreated in 0.2N HCl for 20
min and in a pretreatment solution at 80°C for 30 min
followed by protease digestion at 37°C for 26 min.
Appropriate amount of hybridization solution containing
directly labelled probes, both SpectrumGreen for the
chromosome 17 centromere (CEP17) and SpectrumOr-
ange for the HER2 gene locus, was applied, and the
probe-target tissue was codenatured for 5 min at 72°C
 
a 
b 
c 
Figure 1 Image outputs of the digital analyses. Tissue microarray
images scored by digital analysis as 0/1+ 2+ and 3+ (a. b. and c.
respectively): green lines outline cell membranes revealing positive HER2
immunohistochemical staining by membrane connectivity estimate.
Laurinaviciene et al. Diagnostic Pathology 2011, 6:87
http://www.diagnosticpathology.org/content/6/1/87
Page 3 of 10using Hybridizer (DAKO Diagnostics, Glostrup, Den-
mark) and allowed to hybridize for 19 h at 37°C. Non-
hybridized probe was washed out in a hot 72°C 2 × SSC
with 0.3% NP-40 solution for 2 min. Nuclei were coun-
terstained with DAPI and coverslipped (Invitrogen Cor-
poraton, Carlsbad, USA). Appropriate amplified and
non-amplified in-house controls were processed in the
run. Hybridized probes were examined manually by
fluorescence Zeiss microscope (Zeiss, Axio Imager.Z2,
Gottingen, Germany) equipped with a single green,
orange and triple band pass filter Dapi-FITC-Cy3.
The FISH analyses for HER2 were performed manually
without knowledge of the IHC result, according to Food
and Drug Administration (FDA) scoring system in which
HER2 gene amplification was set at an HER2/CEP17 ratio
of more than 2. One evaluation per patient was performed
after a review of a patient’s spots in the TMAs and selec-
t i o no far e p r e s e n t a t i v ea r e ai no n eo ft h es p o t sf o rt h e
FISH count (a total of 20 cells counted per patient).
Statistical analysis
The agreement between VE1, VE2, and DA was tested by
spot and by patient. The latter was based on the maximum
HER2 score among the 2-4 spots belonging to the same
patient (VE1max, VE2max, DAmax). The agreement was
analyzed using kappa statistics; the strength of agreement
0.81-1.00 was interpreted as almost perfect [13]. The
results are presented as weighted kappa with 95% confi-
dence interval (CI). Pearson’s correlation was performed
to test the linear relationships between the continuous
variable of membrane connectivity estimate and FISH
results. Statistical analysis was performed with SAS 9.2
software.
Results
Sample (spot) adequacy
A total of 737 TMAs spots were evaluated visually by
the pathologist twice (VE1 and VE2). After exclusion of
spots containing inadequate samples or DCIS (n = 9),
575 spots remained for further analysis.
Concordance of visual evaluation and digital analysis (by
spot)
The pathologist intra-observer (VE1 versus VE2) agree-
ment on HER2 score was almost perfect: kappa 0.91, 95%
CI 0.88 - 0.95, Table 1. The percentage agreement was
96.0%. VE2 resulted in 4 spots shifting from 2+ to 3+
category and 4 spots from 3+ to 2+. Interestingly, VE2
“upgraded” 1 5s p o t sf r o m0 / 1 +t o2 +b u tn os p o t sw e r e
“downgraded” from 2+ to 0/1+.
Agreement between the VE and DA was almost perfect:
VE1 versus DA, kappa - 0.86, 95% Cl: 0.81 - 0.90, VE2
versus DA, kappa - 0.87, 95% Cl: 0.82 - 0.91 (Table 1).
The corresponding percentage agreement was 93.2% and
93.4%. In both analyses great majority of HER2 negative
(0/1+) and positive (3+) spots by VE1 and VE2 were clas-
sified as such by the DA. Most of the discordance was
present in the 2+ category where 72% and 65% of the 2+
spots by VE1 and VE2, respectively, were scored 2+ by
the DA. On the other hand, 32 and 21 (6.5 and 4.4%)
spots were recruited by the DA into 2+ category from the
0/1+ category by VE1 and VE2, respectively. Remarkably,
no spots were discrepant in the interval of two categories
(0/1+®3+ or 3+®0/1+).
Concordance of visual evaluation and digital analysis (by
patient)
To test the concordance of VE and DA score on a
patient level, the cases with 2, 3 or 4 adequate spots (by
both VE and DA) per patient were selected. Out of the
177 cases with a total of 575 adequate spots, 16, 15, 55,
and 91 cases contained 1, 2, 3, and 4 adequate spots,
respectively, thus leaving 161 patients with 2, 3 or 4
spots for further analysis.
Patient’s IHC HER2 score was defined as maximum
score (VE1max, VE2max, DAmax) obtained from the 2-4
spots analyzed. Remarkably, variation of the HER2 score
between patient’ss p o t sw a sr a t h e rl o w :a l l( 2 ,3o r4 )
spots revealed the same score in 156, 151, and 141
patients evaluated by VE1, VE2, and DA, respectively
(Table 2). Thus, in a great majority of the 161 patients,
the individual spots produced the same result per patient
which would be identically expressed as maximum,
mode, or median. The remaining 4, 10, and 19 patients
(VE1, VE2, and DA, respectively) revealed a range of 1;
remarkably, the great majority of this variation was
Table 1 Concordance of HER2 immunohistochemistry
visual evaluation and digital analysis by each tissue
microarray spot
VE1 HER2 score VE2 HER2 score
0/1+ 2+ 3+ Total
0/1+ 475 15 0 490
2+ 0 21 4 25
3+ 0 4 56 60
VE1 HER2 score DA HER2 score
0/1+ 2+ 3+ Total
0/1+ 458 32 0 490
2+ 4 18 3 25
3+ 0 0 60 60
VE2 HER2 score DA HER2 score
0/1+ 2+ 3+ Total
0/1+ 454 21 0 475
2+ 8 26 6 40
3+ 0 3 57 60
The concordance per spot is based on individual TMA spot HER2 score value:
VE1 and VE2 - first and second visual evaluation by the pathologist; DA -
digital analysis score.
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the “inter-spot” r a n g eo f2b yV E 1( 3s p o t sg r a d e d0 / 1 + ,
2+, 3+ versus 2+, 2+, 3+ by both VE2 and DA) with FISH
ratio of 2.15 (potential false-negative if only the VE1 per-
formed only on the first spot). Another patient revealed
an “inter-spot” range of 2 by DA (4 spots graded 3+, 1+,
1+, 1+ versus 2 + ,2 + ,2 + ,1 +a n d2 + ,2 + ,2 + ,2 +b yV E 1
and VE2, respectively) with FISH ratio of 1.47 (potential
false-positive if only the DA performed only on the first
spot and/or DAmax used as the patient’s HER2 score).
The pathologist intra-observer (VE1max versus
VE2max) agreement on HER2 score was almost perfect:
kappa 0.88, 95% CI0.81-0.96 (Table 3). The percentage
agreement was 94.4%. By the VE2max, the number of 2+
patients increased from 8 to 15 due to 7 and 1 patients
moving from VE1 0/1+ and 3+ categories, respectively.
The agreement between the visual and digital evalua-
tion was almost perfect: VE1max versus DAmax, kappa
0.80, 95% CI 0.70-0.89; the VE2max versus DAmax,
kappa 0.86, 95% CI 0.79-0.94 (Table 3). The percentage
agreement was 89.4% and 92.5%, respectively. In all three
analyses, 17 patients remained in the 3+ category. Simi-
larly, 122 (80%) and 121 (94%) of HER2 negative (0/1+)
patients by the VE1max and VE2max, respectively, were
classified as such by the DA. Again, most of the discre-
pancies were present in the 2+ category where 62-73% of
the 2+ patients by the VEmax were classified by DAmax
as 2+. In general, the DAmax tended to “upgrade” HER2
score in some patients, shifting them from 0/1+ and 2+
categories into 2+ and 3+, accordingly. Remarkably, no
discrepancies between the VEmax and DAmax in the
interval of two categories were detected.
Proportion of HER2 FISH-positive cases in the IHC
categories scored by the visual evaluation and digital
analysis
HER2 FISH test was performed on the sections from the
same TMAs containing the 575 spots used for the IHC
analysis. FISH results of overall 152 patients were
obtained and compared with the HER2 IHC results
(Table 4). The raw data of the patients with IHC score
2+ or 3+ (by either visual evaluation or digital analysis)
and/or FISH HER2/CEP17 ratio > 2.0 and/or CEP17 >
3.0 is presented in the Table 5.
The same 5 FISH-positive patients were present in the
merged category of IHC 0 or 1+, established by all evalua-
tions (VE1max, VE2max, and DAmax). The HER2/CEP17
Table 2 Patients’ HER2 immunohistochemistry score in
the TMAs represented by a range and maximum spot
value
VE1range VE1max
0/1+ 2+ 3+ Total
0 136 4 16 156
1 0 * 404
20 * 0 * 1 1
VE2range VE2max
0/1+ 2+ 3+ Total
0 129 6 16 151
1 0 * 911 0
20 0 * 0 0
DArange DAmax
1 2 3 Total
0 122 3 16 141
10 * 1 6 3 1 9
20 * 0 * 1 1
* the range cannot logically be 1 or 2.
The cross tabulation of the patients’ HER2 score range and maximum values
represents variation of the analysis results between individual patient’s spots.
VE1max and VE2max - first and second visual evaluation by the pathologist,
DAmax - digital analysis score. Accordingly, VE1range, VE2range, and DArange
represent range between a minimum and maximum spot HER2 score value.
Table 3 Concordance of HER2 immunohistochemistry
maximum TMA score by visual evaluation and digital
analysis
VE2max HER2 score
VE1max HER2 score 0/1+ 2+ 3+ Total
0/1+ 129 7 0 136
2 + 0 718
3+ 0 1 16 17
DAmax HER2 score
VE1max HER2 score 0/1+ 2+ 3+ Total
0/1+ 122 14 0 136
2 + 0 538
3+ 0 0 17 17
DAmax HER2 score
VE2max HER2 score 0/1+ 2+ 3+ Total
0/1+ 121 8 0 129
2+ 1 11 3 15
3+ 0 0 17 17
The concordance per patient is based on maximum TMA spot HER2 score
value: VE1max and VE2max - first and second visual evaluation by the
pathologist, DAmax - digital analysis score.
Table 4 Proportion of HER2 FISH-positive cases in the
IHC score categories by visual evaluation and digital
analysis
HER2 FISH positive (%)
HER2 score VE1max VE2max DAmax
0/+1 8/127 (6.3) 7/120 (5.8) 5/113 (4.4)
2+ 2/8 (25.0) 2/15 (13.3) 3/19 (15.8)
3+ 14/17 (82.4) 15/17 (88.2) 16/20 (80.0)
Total 152 152 152
Number and percentage (in parentheses) of FISH-positive patients in the IHC
score categories by maximum TMA spot HER2 score value: VE1max and
VE2max - first and second visual evaluation by the pathologist, DAmax -
digital analysis score.
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patient revealing HER2 gene clusters with HER2/CEP17
ratio of 4.6 (Table 5, lines 10-14). These 5 cases were not
likely to be false-negative by IHC since their initial (diag-
nostic; data not shown) IHC result was negative and no
issues with formalin fixation of the samples were noted. In
the category 0/1+ (Table 4), VE2max, and VE1max
included additional (2 and 3, respectively) FISH-positive
patients with the HER2/CEP17 ratio of 2.1, 2.2, and 4.5
(Table 5, lines 21, 22, 29; potential false-negatives if only
the visual evaluations were performed).
In the categories of IHC 2+ and 3+ (Table 4), most
(3+16 = 19) FISH-positive patients were detected by
DAmax, followed VE2max (2+15 = 17), and VE1max
(2+14 = 16). On the other hand, DAmax 3+ picked up
4 patients with the HER2/CEP17 ratio 1.4-1.7 (Table 5,
lines 35, 38-40), however, 1 of these patients (line 38)
revealed the gene amplification along with polysomy
(mean HER2 = 9.0; CEP17 = 5.2). The same 4 patients
fell into either 3+ or 2+ category by VE1max and
VE2max.
In summary, DAmax appeared to be most accurate
with respect to positive FISH results. For the most of
the cases where discrepancy was observed between IHC
and FISH, the VE and DA were in agreement, and the
discrepancy therefore seemed to be related to either bio-
logical variation of HER2 amplification and expression,
or due to mistakes in reagents or assay procedures.
Correlation of membrane connectivity estimate with HER2
FISH results
Digital analysis of the IHC HER2 is based on the continu-
ous variable of membrane connectivity and can be used in
analyses of biomarker expression, independently of catego-
rical scoring systems. We explored the potential of the
membrane connectivity estimate comparing it to the
patient’s HER2 FISH data. Maximum spot value (Connect-
Max) was used to characterize the patient’s membrane
connectivity estimate. Distribution analysis of the Con-
nectMax revealed pronounced bimodal pattern with left
asymmetry (Figure 2). Significant correlations between log
(ConnectMax) and the FISH results were observed: log
(mean HER2) copy number per cell (r = 0.67, p < 0.0001),
log(mean HER2/CEP17) ratio (r = 0.57, p < 0.0001), and
mean CEP17 number per cell (r = 0.39, p < 0.0001).
Table 5 Raw data of the FISH, visual evaluation and
digital analysis results
Line # Her2/CEP17 HER2 CEP17 VE1max VE2max DAmax
1 0,4 1,8 4,2 1 1 1
2 0,5 2,1 4,4 1 1 1
3 0,5 1,9 3,5 1 1 1
4 0,9 3,0 3,4 1 1 1
5 1,1 3,7 3,5 1 1 1
6 1,3 4,2 3,3 1 1 1
7 1,7 5,4 3,1 1 1 1
8 1,8 5,7 3,2 1 1 1
9 1,8 7,1 3,9 1 1 1
10 2,1 2,7 1,3 1 1 1
11 2,3 4,2 1,9 1 1 1
12 2,4 3,2 1,3 1 1 1
13 2,7 3,8 1,4 1 1 1
14 4,6 12,6 2,8 1 1 1
15 1,2 1,8 1,6 1 1 2
16 1,3 2,3 1,8 1 1 2
17 1,4 5,7 3,9 1 1 2
18 1,5 6,7 4,5 1 1 2
19 1,6 4,3 2,7 1 1 2
20 1,6 5,3 3,3 1 1 2
21 2,1 3,8 1,8 1 1 2
22 4,5 4,5 1,0 1 1 2
23 0,5 1,5 2,9 1 2 1
24 1,0 2,1 2,1 1 2 2
25 1,3 4,7 3,7 1 2 2
26 1,4 4,1 2,8 1 2 2
27 1,7 5,8 3,5 1 2 2
28 2,0 5,4 2,8 1 2 2
29 2,2 4,3 1,9 1 2 2
30 1,0 4,9 4,7 2 2 2
31 1,1 4,1 3,7 2 2 2
32 1,2 3,0 2,4 2 2 2
33 1,3 5,0 3,8 2 2 2
34 1,4 3,3 2,4 2 2 2
35 1,5 3,3 2,2 2 2 3
36 3,4 11,3 3,4 2 2 3
37 6,5 12,4 1,9 2 3 3
38 1,7 9,0 5,2 3 2 3
39 1,4 2,6 1,8 3 3 3
40 1,5 4,6 3,1 3 3 3
41 2,3 4,3 1,9 3 3 3
42 4,5 4,5 1,0 3 3 3
43 4,7 10,1 2,2 3 3 3
44 4,9 11,2 2,3 3 3 3
45 4,9 15,5 3,2 3 3 3
46 5,4 13,8 2,6 3 3 3
47 5,9 16,8 2,9 3 3 3
48 6,5 20,4 3,2 3 3 3
49 6,8 13,6 2,0 3 3 3
50 7,2 22,7 3,2 3 3 3
51 7,2 23,2 3,2 3 3 3
Table 5 Raw data of the FISH, visual evaluation and digi-
tal analysis results (Continued)
52 8,3 22,0 2,7 3 3 3
53 13,1 28,2 2,2 3 3 3
54 13,3 38,5 2,9 3 3 3
The raw data of the patients with IHC score 2+ or 3+ (by either visual
evaluation or digital analysis) and/or FISH HER2/CEP17 ratio > 2.0 and/or
CEP17 > 3.0
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FISH variables raise an issue of understanding the com-
plexity of the phenomena depicted in the bubble plot
(Figure 3). Most IHC- and FISH-negative cases are
represented by small dots in the left lower quadrant,
while the positive cases concentrate in the left upper
quadrant. However, quite numerous IHC-negative and
IHC-positive cases fall into the “polysomy” quandrants
on the right. The few IHC-FISH discrepancies can be
tracked on the diagram, some of them revealing exam-
ples where conventional criteria for HER2 gene amplifi-
cation testing by FISH may not always work. In
particular, note the IHC-positive case with a high polys-
omy and mean HER2 per cell above 6, but the HER2/
CEP17 ratio below 2 (also, Table 5, line 38). Multivariate
analysis of the IHC and FISH parameters may help
understanding these complexities, and the membrane
connectivity estimate may serve as a continuous variable
of the IHC positivity.
Discussion
Our experiment revealed a reliable performance of
HER2 expression measurement by the IHC digital image
analysis based on the membrane connectivity estimate.
The algorithm was run “plug-and-play” on the TMA
images without an attempt to calibrate for potential
image variation caused by scanning or IHC procedures.
Manual annotation of the tumour tissue was not per-
formed; however, spots containing DCIS or insufficient
amount of tumour tissue were excluded from digital
analysis by visual evaluation. Under these conditions,
the digital analysis was in almost perfect agreement with
the pathologist’s score (VE) and exceeded the latter in
terms of detecting FISH-positive patients.
We tested the agreement between the visual and digital
evaluations in two sets of analyses: it was almost perfect
at the level of individual spot (kappa 0.86 and 0.87, with
the VE1 and VE2 respectively) and at the patient level
(kappa 0.80 and 0.86, with the VE1max and VE2max,
respectively). In general, the level of agreement in our
study was among the highest reported when compared to
that of previous studies using various digital analysis plat-
forms [5,6,9,10,14-17], but obviously some caution has to
be taken when comparing across studies with different
designs. In both VE and DA, we used maximum TMA
spot values to define patient’sH E R 2I H Cs t a t u s .T h i s
approach has been tested previously [18], and, in our
view, is a better way to summarize TMA data per patient
than mean or median value, especially, when tissue het-
erogeneity is a concern. Also, maximum spot value
increases the sensitivity of HER2 detection and may com-
pensate for the limited tissue sampling in TMA.
As expected from the previous studies [6,14,15], both
0/1+ and 3+ IHC categories were consistently discrimi-
nated by both the VE and DA, whereas most discrepan-
cies were present in detection of the 2+ score category.
Although it sounds like a paradox, these discrepancies
may bring the greatest “added value” of integrating digital
analysis into the routine pathology work-up of HER2
testing. Extrapolation of our experiment to clinical set-
ting would mean that in the cohort of 152 patients with
Figure 2 Histogram of distribution of the patients by their
maximum TMA spot HER2 membrane connectivity estimate.
Histogram plot represents distribution of the patients by their
maximum spot HER2 membrane connectivity estimate.
Figure 3 Bubble plot display of interrelationship between the
HER2 membrane connectivity estimate and HER2 FISH data.
Horizontal axis represents mean CEP17 by FISH analysis. Left vertical
axis represents mean HER2 by FISH analysis. Right vertical axis
represents HER2/CEP17 ratio. Bubble size is proportional to the
patient’s maximum HER2 connectivity value. Black dashed vertical
reference line separates cases with polysomy (CEP17 > 3) to the
right. Blue and orange dashed horizontal reference lines separate
cases with amplification (HER2 > 6 and HER2/CEP17 > 2) above.
Each patient is represented by two bubbles with the same CEP17
value: blue bubble maps to the mean HER2 orange bubble - to the
mean HER2/CEP17 ratio.
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ated by one pathologist once (VE1max) would have
revealed 8 patients with HER2 IHC 2+ with 8 reflex FISH
tests performed. Including the DA would have resulted
in additional 14 HER2 IHC 2+ cases followed by the obli-
gatory 14 FISH tests, thus detecting another 3 HER2-
amplified cases (Table 5, lines 21, 22, 29). If the decision
to perform a reflex FISH test were based on the IHC 2+
score by either VE1max or DA, that would have resulted
in 19 FISH-positive cases compared to 16 by the
VE1max-based decision alone (leading to 19% increase of
the number of HER2-amplified cases in the cohort). In
the setting where the pathologist would evaluate the IHC
twice (VE1max and VE2max), the second review would
have resulted in additional 8 HER2 IHC 2+ cases fol-
lowed by the obligatory 8 FISH tests, thus detecting 1
additional HER2-amplified case; inclusion of the DA
results into the account would require another 8 FISH
tests with another 2 HER2-amplified cases detected. Con-
sidering potential consequences of a misdiagnosed HER2
status in 2 or 3 patients in the cohort of 152 for the
“price” of adding automated digital analysis step and
roughly 5-8 additional FISH tests per misdiagnosed case,
the “balance” seems to be on the positive side. On the
other hand, addition of the DA would have “saved” 2o r3
FISH tests (compared to VE2max and VE1max, respec-
tively) by suggesting the IHC 3+ score instead of the
pathologist’s 2+ score (Table 5, lines #35-37), however,
o n eo ft h ec a s e s( # 3 5 )w a sn e g a t i v eb yF I S H ,r e v e a l i n g
potential lack of specificity of the DA alone. In contrast to
other studies [19,20], our DA did not give a promise of a
decreased number of IHC 2+ cases or increased specificity
in detecting HER2-amplified cases. This latter statement,
however, must be taken with caution since individual
“sensitivity” of the pathologists may shift the VE results in
different directions relative to the DA (the inter-observer
variability was not tested in the present study). In sum-
mary, we suggest that the membrane connectivity DA
would be most useful as a decision-support and quality
assurance tool, alerting pathologists of borderline 0/1+
versus 2+ and 2+ versus 3+ HER2 IHC cases, thus improv-
ing the accuracy of the HER2 testing, but without expecta-
tion of significant savings by avoiding unnecessary FISH
tests. Nevertheless, improved accuracy of the HER2 test-
ing, without having to perform FISH in all cases, presents
a reasonable economic trade-off. Although these consid-
erations are based on the TMA analyses, whereas current
pathology HER2 testing routine is based in the whole
section samples, our data is at least representative and
simulates the cases when limited tumour samples are
available for testing.
The pathologist intra-observer agreement was slightly
better than that with the digital analysis. However, the
DA appeared to be more accurate in detection of FISH-
positive patients. Interestingly, the second visual evalua-
tion (VE2) was slightly more “sensitive” than VE1: it
detected more 2+ patients and rescued 1 FISH-positive
patient from the 0/1+ category by VE1. It is likely
that this increase of sensitivi t yi sar e s u l to fal e a r n i n g
curve - the pathologist adapting to evaluation of small
samples of tissue in the TMAs as opposed to the IHC
whole section slides used in routine pathology practice.
This aspect may present additional benefit of the DA
not only in the TMA analyses but also when a small
tumour sample is available.
Objectivity of the digital analysis depends on numerous
factors [8]; one particular factor is the accuracy of
tumour tissue sampling for the analysis. If non-tumour
tissue is included in the analysis, it may “dilute” the per-
centage of positive cells. In our experiment, no manual
or automated annotation of the tumour tissue was per-
formed, nevertheless, the DA recruited more 2+ and 3+
spots and patients than VE. Inevitably, our TMA spots
contained variable proportions of tumour and non-
tumour tissues and the digital analysis results could have
been distorted without proper selection of the tumour
tissue. However, since the membrane connectivity is a
non-cell-based estimate and does not require distinction
between tumour and non-tumour cells, the only prere-
quisite for the digital analysis was a sufficient amount but
not proportion of tumour tissue in the ROI. This also
provided the benefit of avoiding manual annotation of
the ROI - the laborious and potentially biasing step of
the image analysis.
With regard to detection of FISH-positive patients, the
digital analysis provided maximum accuracy of IHC
interpretation possible in our TMAs. As outlined in the
Results section, the “false-positive” and “false-negative”
cases by DAmax were also discrepant by VE1max and
VE2max and most likely represented a true biological
variation of HER2 gene amplification and expression
and/or possible issues in tissue processing [21-26].
Although HER2 FISH status is commonly used as a “gold
standard” in HER2 IHC studies, in a small proportion of
cases it may remain discrepant due to tissue heterogene-
ity, CEP17 polysomy/amplification (if only HER2/CEP17
ratio is used to define the HER2 status), or other unrec-
ognized causes of variation [27-30]. Our data reveal a
subpopulation of patients where conventional HER2
FISH positivity criteria based on HER2/CEP17 ratio may
be not sufficient and support the need to further explore
the biological continuum of HER2 positivity and clinical
relevance of the test [30-33]. Although analysis of this
complexity is beyond the scope of the present study, it is
important to note that the membrane connectivity esti-
mate represents a continuous variable of HER2 expres-
sion by IHC and can serve better than categorical IHC
score in statistical analyses exploring the relationships of
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Page 8 of 10HER2 expression and amplification. In support of this
perspective, we found significant correlations of the IHC
membrane connectivity with the FISH results: HER2
copy number (r = 0.67), HER2/CEP17 ratio (r = 0.57),
and mean CEP17 number per cell (r = 0.39), similar to
the recent report of Vranek et al [34] (although the corre-
lation to CEP17 did not reach statistical significance in
this study of patients with the CEP17 polysomy). Of note,
automation and further quantification of the FISH test-
ing, with increase of accuracy and capacity of the test,
seems to be an important step to further progress.
Conclusions
In conclusion, HER2 IHC digital image analysis based
on membrane connectivity estimate, tested on early duc-
tal carcinoma of the breast tissue microarrays, was in
almost perfect agreement with the visual evaluation of
the pathologist and more accurate in detection of HER2
FISH-positive patients. Most immediate benefit of inte-
grating the DA algorithm into the routine pathology
HER2 testing may be obtained by alerting/reassuring
pathologists of potentially misinterpreted IHC 0/1+ ver-
sus 2+ cases. The algorithm was used without manual
or automated annotation of tumour tissue and appeared
to be independent of the proportion of tumour in the
tissue analyzed. It provided a continuous variable
reflecting HER2 IHC expression and could be useful for
quality assurance, computer-assisted diagnosis, and
HER2 amplification/expression heterogeneity studies.
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